About POINT Biopharma
POINT Biopharma is a company based in Mississauga (Canada) founded in 2019 was acquired by Lilly in October 2023.. POINT Biopharma has raised $20 million across 1 funding round from investors including Lilly. POINT Biopharma operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Lantheus, among others.
- Headquarter Mississauga, Canada
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Point Biopharma Global Inc.
-
Annual Revenue
$226.58 M0as on Dec 31, 2022
-
Net Profit
$98.29 M314as on Dec 31, 2022
-
EBITDA
$125.52 M376as on Dec 31, 2022
-
Total Equity Funding
$20 M (USD)
in 1 rounds
-
Latest Funding Round
$20 M (USD), Series A
Aug 04, 2020
- Investors
-
Employee Count
Employee Count
-
Acquired by
Lilly
(Oct 03, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of POINT Biopharma
POINT Biopharma has successfully raised a total of $20M through 1 strategic funding round. The most recent funding activity was a Series A round of $20 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $20.0M
-
First Round
First Round
(04 Aug 2020)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Series A - POINT Biopharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in POINT Biopharma
POINT Biopharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Lilly. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by POINT Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - POINT Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Point Biopharma Comparisons
Competitors of POINT Biopharma
POINT Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Lantheus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| domain | founded_year | HQ Location |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
|
|
| domain | founded_year | HQ Location |
Developer of diagnostic imaging agents and targeted therapeutics
|
|
| domain | founded_year | HQ Location |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Point Biopharma
Frequently Asked Questions about POINT Biopharma
When was POINT Biopharma founded?
POINT Biopharma was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is POINT Biopharma located?
POINT Biopharma is headquartered in Mississauga, Canada. It is registered at Mississauga, Ontario, Canada.
Who is the current CEO of POINT Biopharma?
Joe Mccann is the current CEO of POINT Biopharma.
Is POINT Biopharma a funded company?
POINT Biopharma is a funded company, having raised a total of $20M across 1 funding round to date. The company's 1st funding round was a Series A of $20M, raised on Aug 04, 2020.
What is the annual revenue of POINT Biopharma?
Annual revenue of POINT Biopharma is $226.58M as on Dec 31, 2022.
What does POINT Biopharma do?
POINT Biopharma was founded in 2019 and is based in Mississauga, Canada. Radiopharmaceuticals for cancer treatment are developed by the company within the biotechnology sector. CanSEEK technology is employed to reduce toxicity through activation of targeting moieties, such as ligands, minimizing off-target effects. The pipeline features PNT2002 as a PSMA-targeted therapy for metastatic castration-resistant prostate cancer and PNT2001 as a next-generation PSMA-targeted radioligand.
Who are the top competitors of POINT Biopharma?
POINT Biopharma's top competitors include Advanced Accelerator Applications, SOFIE and AdvanCell.
Who are POINT Biopharma's investors?
POINT Biopharma has 1 investor. Key investors include Lilly.